These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27230864)

  • 1. The Items Predicting Non-Remission after 6 Months of Treatment of Patients with Generalized Anxiety Disorder Covered the Eysenck Neuroticism Components of Anxiety, Interpersonal Sensitivity and Depression.
    Bech P; Rickels K
    Psychother Psychosom; 2016; 85(4):229-30. PubMed ID: 27230864
    [No Abstract]   [Full Text] [Related]  

  • 2. Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder.
    Jung J; Tawa EA; Muench C; Rosen AD; Rickels K; Lohoff FW
    Psychiatry Res; 2017 Aug; 254():8-11. PubMed ID: 28437668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR.
    Rickels K; Etemad B; Rynn MA; Lohoff FW; Mandos LA; Gallop R
    Psychother Psychosom; 2013; 82(6):363-71. PubMed ID: 24061331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Comorbid Adult Attention-deficit/Hyperactivity Disorder and Generalized Anxiety Disorder: 2 Case Reports.
    Oliva F; Carezana C; Nibbio G; Bramante S; Portigliatti Pomeri A; Maina G
    J Psychiatr Pract; 2018 Jul; 24(4):292-298. PubMed ID: 30427813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher venlafaxine serum concentrations necessary for clinical improvement? Time to re-evaluate the therapeutic reference range of venlafaxine.
    Scherf-Clavel M; Hommers L; Wurst C; Stonawski S; Deckert J; Domschke K; Unterecker S; Menke A
    J Psychopharmacol; 2020 Oct; 34(10):1105-1111. PubMed ID: 32669065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship of social anxiety disorder symptoms with probable attention deficit hyperactivity disorder in Turkish university students; impact of negative affect and personality traits of neuroticism and extraversion.
    Evren C; Dalbudak E; Ozen S; Evren B
    Psychiatry Res; 2017 Aug; 254():158-163. PubMed ID: 28460287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining response and remission in anxiety disorders: toward an integrated approach.
    Bandelow B
    CNS Spectr; 2006 Oct; 11(10 Suppl 12):21-8. PubMed ID: 17008827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.
    Sheehan DV
    J Clin Psychiatry; 2001; 62 Suppl 19():26-31. PubMed ID: 11577788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venlafaxine induced QTc interval prolongation in a therapeutic dose.
    Bavle A
    Asian J Psychiatr; 2015 Aug; 16():63-4. PubMed ID: 26187237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanonychia induced by venlafaxine hydrochloride.
    Mercuri SR; Paolino G; Mavilia L; Didona D; Brianti P
    G Ital Dermatol Venereol; 2019 Aug; 154(4):495-496. PubMed ID: 29192476
    [No Abstract]   [Full Text] [Related]  

  • 11. Psychometric validation of the Hopkins Symptom Checklist (SCL-90) subscales for depression, anxiety, and interpersonal sensitivity.
    Bech P; Bille J; Møller SB; Hellström LC; Østergaard SD
    J Affect Disord; 2014 May; 160():98-103. PubMed ID: 24445132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed Sinus Tachycardia Associated With Venlafaxine Administration: A Unique Case Report and Discussion.
    Osuagwu FC; Bradley R
    J Clin Psychopharmacol; 2019; 39(6):689-690. PubMed ID: 31688406
    [No Abstract]   [Full Text] [Related]  

  • 13. Venlafaxine-Associated Euprolactinemic Galactorrhea and Hypersexuality: A Case Report and Review of the Literature.
    Warren MB
    J Clin Psychopharmacol; 2016 Aug; 36(4):399-400. PubMed ID: 27219091
    [No Abstract]   [Full Text] [Related]  

  • 14. Measuring euthymia within the Neuroticism Scale from the NEO Personality Inventory: A Mokken analysis of the Norwegian general population study for scalability.
    Bech P; Carrozzino D; Austin SF; Møller SB; Vassend O
    J Affect Disord; 2016 Mar; 193():99-102. PubMed ID: 26773899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The validity of dysthymia to predict clinical depressive symptoms as measured by the Hamilton Depression Scale at the 5-year follow-up of patients with first episode depression.
    Bech P; Kessing LV; Bukh JD
    Nord J Psychiatry; 2016 Nov; 70(8):563-6. PubMed ID: 27181030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. To be sure, to be sure: intolerance of uncertainty mediates symptoms of various anxiety disorders and depression.
    McEvoy PM; Mahoney AE
    Behav Ther; 2012 Sep; 43(3):533-45. PubMed ID: 22697442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodology and preliminary results from the neurobiology of late-life depression study.
    Steffens DC; Manning KJ; Wu R; Grady JJ; Fortinsky RH; Tennen HA
    Int Psychogeriatr; 2015 Dec; 27(12):1987-97. PubMed ID: 26323208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and environmental sources of covariation between generalized anxiety disorder and neuroticism.
    Hettema JM; Prescott CA; Kendler KS
    Am J Psychiatry; 2004 Sep; 161(9):1581-7. PubMed ID: 15337647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships of neuroticism and extraversion with axis I and II comorbidity among patients with DSM-IV major depressive disorder.
    Jylhä P; Melartin T; Isometsä E
    J Affect Disord; 2009 Apr; 114(1-3):110-21. PubMed ID: 18687471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Categorical and dimensional stability of comorbid personality disorder symptoms in DSM-IV major depressive disorder: a prospective study.
    Melartin TK; Haukka J; Rytsälä HJ; Jylhä PJ; Isometsä ET
    J Clin Psychiatry; 2010 Mar; 71(3):287-95. PubMed ID: 20079331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.